Posted by Michael Wonder on 01 Aug 2024
SanBio obtains marketing approval for Akuugo suspension for intracranial implantation (vandefitemcel) as a therapeutic agent for improving chronic motor paralysis from traumatic brain injury
31 July 2024 - SanBio hereby announces that today on 31 July 2024, it obtained conditional and time limited marketing approval for the human somatic stem cell-processed product “Akuugo suspension for intracranial implantation” (vandefitemcel) in Japan, for the indication of improving chronic motor paralysis resulting from traumatic brain injury.
The approval of Akuugo was based on the results of the global Phase 2 clinical trial SanBio conducted in Japan and the US.
